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Abstract
This study was conducted in order to map European research in chronic respiratory dis-
eases (CRDs). It was intended to assist the European Commission and other research
funders to identify gaps and overlaps in their portfolios, and to suggest ways in which they
could improve the effectiveness of their support and increase the impact of the research on
patient care and on the reduction of the incidence of the CRDs. Articles and reviews were
identified in the Web of Science on research in six non-communicable respiratory diseases
that were published in 2002–13 from 31 European countries. They represented only 0.8%
of biomedical research output but these diseases accounted for 4.7% of the European dis-
ease burden, as measured by Disability-Adjusted Life Years (DALYs), so the sub-field is
seriously under-researched. Europe is prominent in the sub-field and published 56% of
the world total, with the UK the most productive and publishing more than France and Italy,
the next two countries, combined. Asthma and Chronic Obstructive Pulmonary Disease
(COPD) were the diseases with the most publications and the highest citation rates.
They also received the most funding, with around two acknowledgments per paper (in
2009–13), whereas cystic fibrosis and emphysema averaged only one. Just over 37% of
papers had no specific funding and depended on institutional support from universities and
hospitals.
Introduction
Chronic Respiratory Diseases (CRDs) include a wide range of non-communicable conditions—
such as Chronic Obstructive Pulmonary Disease (COPD), emphysema, allergic rhinitis, asthma,
pulmonary arterial hypertension and cystic fibrosis with pulmonary manifestations—which have
the common characteristic of adversely affecting patient airways and lung structures [1]. They
are usually distinct from communicable ones, such as tuberculosis and influenza.
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Across both the developed and the developing world, CRDs are a major public health prob-
lem. In developing countries, they are associated with poverty, pollution and poor access to
health care resources [2]. In industrialized countries of the European Union, they are associ-
ated with increased tobacco-use, obesity, socio-economic inequalities and limited access to
healthcare resources [3]. In the year 2000, COPD was the fourth leading cause of mortality
responsible for 2.8 million deaths [4]. The World Bank/World Health Organization has pro-
jected that by 2020, COPD will rank as the fifth most debilitating condition in the world, in
terms of worldwide burden of disease [5].
The two major components of CRDs are COPD and asthma. COPD includes a number of
specific lung conditions, characterised by progressive airflow limitation, often a pulmonary
response to noxious particles or gases, such as tobacco smoke [6]. It is both progressive and
irreversible, and can exacerbate co-morbidities such as lung cancer and cardiovascular disease
[7]. COPD is recognized as a systemic inflammatory disorder with numerous additional pul-
monary and extrapulmonary manifestations, including an increased risk for development of
primary lung cancers [8]. It can also lead to weight loss and skeletal muscle dysfunction [9].
Asthma is caused by the hyper-responsiveness of the bronchi and trachea to particular stimuli
and occurs through narrowing of the airways; it appears to be occasioned by both environmen-
tal and genetic factors [10]. Symptoms include tightness in the chest, coughing, wheezing and
shortness of breath, and can be alleviated by means of inhalers with bronchodilators or gluco-
corticosteriods [11].
World-wide, the prevalence of these CRDs is increasing and the percentage of deaths rose
from 6.5% in 2002 to 7.2% in 2010, although many sufferers, probably the majority, are not
actually diagnosed. Within Europe, the severity of the burden varies greatly, being over 7% in
the UK in 2010 in terms of Disability-Adjusted Life Years (DALYs), but less than 2% in Esto-
nia. In most European countries, the relative burden has decreased since 2002, according to the
WHO Global Burden of Disease estimates from the University of Washington's Institute for
Health Metrics and Evaluation (IHME: http://vizhub.healthdata.org/gbd-compare/), and the
European average has gone down from 5.4% of all DALYs to 4.5%. This probably reflects the
reductions in smoking and coal-mining, and improvements in air quality. However, in the 11
former socialist countries of central and eastern Europe that are now EUMember States, the
burden has gone up from 3.06% to 3.36% and it has increased markedly in Bulgaria and
Poland. The two main diseases are COPD and asthma, averaging 2.9% of all DALYs and 1.1%
respectively in Europe in 2010; the others, including cystic fibrosis, only accounted for 0.7% of
DALYs.
The recent reductions in smoking in western European countries (e.g., from 28% to 22% in
England between 1998 and 2008 [12], and much more in Scandinavia, [13]) will certainly have
helped to reduce the disease burden, especially for cancer, cardiovascular disease and diabetes,
but also for these chronic respiratory diseases. There have also been parallel bans on smoking
in enclosed spaces in the USA, and they have led to declines in acute myocardial infarction [14,
15]. The effects of smoking on asthma and COPD have been described in some detail [16, 17];
they are exacerbated by industrial pollutants [18, 19]. In eastern Europe, and many other coun-
tries, smoking is still increasing, particularly among women, with consequent effects on respi-
ratory diseases. The effects of global warming on climate change may also affect the incidence
of asthma [20, 21], allergic rhinitis (often caused by pollen from ragweed [22, 23]) and COPD
[24].
There appear to be few papers on the outputs of research on these diseases although there
are two on environmental tobacco smoke research [25, 26]. One study revealed that only a
minority of abstracts of clinical trials of treatments for CF presented at conferences were subse-
quently published in the serial literature [27]. A study on the Spanish-language journal,
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Archivos de Bronconeumologia, from 1970 to 2000 with particular reference to research on smok-
ing, looked at the bibliometric characteristics of the articles [28] but did not find any striking
results. A more comprehensive study of all respiratory disease research, including that on lung
cancer, showed that Finland, Canada, Spain and the UK had the greatest relative commitment to
respiratory disease research expressed as a ratio of their share of world biomedical research, and
that charitable funding helped the UK to score well in CF research [29]. Recently, there has been a
study on respiratory research outputs from China, Hong Kong and Taiwan; the former has now
overtaken both of the others in output but its research remains less well cited [30].
The research described here was carried out as part of an investigation for the European
Union (EU) on the outputs of research on five non-communicable diseases (NCDs) in Europe.
This was intended to reveal gaps and overlaps, and to learn more about the funding sources for
this research. [The other four NCDs are cancer, cardiovascular disease (including stroke), dia-
betes and mental disorders, and the findings of the project on these will be published sepa-
rately.] Funding for research on CRDs, as for other medical conditions, comes from four main
sources: national and regional government, private-non-profit organisations (including collect-
ing charities, endowed foundations, hospitals and universities, and voluntary non-profit associ-
ations), industry and international bodies such as the EU. This project was intended to assist
them to understand the research environment in Europe, and to suggest ways in which they
could be more effective in their support of research and of activities that would promote its
transfer to the care of patients and public health campaigns to prevent illness through changes
in behaviour. It was also intended to inform the researchers on the areas of research in need of
more attention, and of which countries could provide relevant expertise to those ones wishing
to improve their capability. The researchers could also use the findings to seek more funding
from external funders and from internal sources.
Methodology
The bibliographic details of papers recorded in the Web of Science published by Thomson Reu-
ters (WoS) were identified by means of a special filter. This was based on title words for the
names of the respiratory diseases separated with Boolean operator “OR” (“asthma OR bronchi-
ectasis OR cystic fibrosis OR CFTR OR COPD OR chronic obstructive respiratory disease OR
emphysema OR mucoviscidosis”), and four specialist journals: “COPD-Journal of Chronic
Obstructive Pulmonary Disease OR International Journal of Chronic Obstructive Pulmonary
Disease OR Journal of Asthma OR Journal of Cystic Fibrosis”. Papers were selected if they had
one of the title words, or were in one of the specialist journals, or both. The WoS software com-
bines the results of separate search statements so that duplicates are eliminated.
"Articles" and "reviews" (as defined in the WoS) from the 12 years, 2002–13, with an address
in one or more of the 28 European Union Member States, plus Iceland, Norway and Switzer-
land, were downloaded to a series of files, 500 at a time. This time frame allowed an adequate
time period for any recent trends to be observed. The list of countries is shown in Table 1, with
their digraph International Standards Organisation (ISO2) codes. They were then transferred
to an Excel spreadsheet by means of a macro written by Philip Roe of Evaluametrics Ltd, St
Albans, UK. The addresses were parsed to show the fractional count of each country in each
paper. (A paper with one German and two French addresses would be counted 0.33 for Ger-
many and 0.67 for France.) Five-year citation counts were determined for the papers published
in 2002–09 to allow fair comparisons between later and earlier papers since previous research
in the domain by the authors have used the same fixed window of time.
However, the impact of medical research can be better gauged from its influence on clinical
practice. This is difficult to judge, but a proxy indicator is the extent to which it has formed the
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evidence base of clinical guidelines, which are being developed and published in increasing
numbers. As part of the EU mapping project, we collected these from 19 different countries,
numbering 45 in total, and matched their cited references to papers in the WoS. We thereby
compiled a database of 7184 references, and could compare the numbers from each European
country, and their percentage of the European total, with the presence of each country in respi-
ratory disease research. This was done on a fractional count basis, both for asthma and for
COPD. Some papers would have been cited on many different guidelines; this would indicate
their importance for guiding clinical practice in Europe.
Comparisons were made between the outputs of the 31 European countries in respiratory dis-
ease research (RESPI) and their wealth, as measured by their Gross Domestic Products (GDP).
Several previous studies [31,32] have demonstrated that there is a close correlation between these
two indicators; they are normally plotted on log-log scales because of their wide variation in val-
ues (several orders of magnitude). The best (least-squares) regression line to fit the data is based
on a power-law, and appears as a straight line on log-log paper. Departures from this line can
then show which countries are performing particularly well or badly, with observed outputs
being compared with those expected on a Poisson distribution with one degree of freedom.
Country relative commitments (RC) to RESPI research were compared with their biomedi-
cal research output in the same years. This was based on a special address filter that was origi-
nally developed to distinguish between biomedical and other papers in multi-disciplinary
journals such as Nature and Science. These were based on integer counts. For research on the
individual diseases, comparisons were made with the European average, and were based on
fractional counts.
Details of the funding sources were obtained from the WoS for papers from 2009–13. The
list of funders given in the WoS included many false positives where companies had remuner-
ated authors for unrelated work declared in a statement of Conflict of Interest [33]. These state-
ments were first identified by means of another macro, and then individually read to redact the
list of explicit funders. There were also implicit funders taken from the addresses–government
research laboratories, charity laboratories, and commercial companies. Papers without either
type of funding would have received institutional support from a university or a hospital.
Because the names of the funders were not standardised, it was necessary to give them codes
so that they could be individually identified. These were in three parts: a trigraph to identify
the funder, e.g., MRC = UKMedical Research Council; a digraph to show their sector and sub-
sector (see Table 2); and their ISO digraph code. The thesaurus contained almost 12,000 indi-
vidual funders, but small funding sources, of which there were very many, were given "generic"
codes that simply identified their sub-sector and country. All codes were manually applied
with the aid of two thesauruses which were developed from previous work; one of funders and
the other of author addresses.
Table 1. List of the 31 European countries whose outputs were examined in this study with their ISO2 codes.
ISO Country ISO Country ISO Country ISO Country
AT Austria EE Estonia IS Iceland PL Poland
BE Belgium ES Spain IT Italy PT Portugal
BG Bulgaria FI Finland LT Lithuania RO Romania
CH Switzerland FR France LU Luxembourg SE Sweden
CY Cyprus GR Greece LV Latvia SI Slovenia
CZ Czech Rep. HR Croatia MT Malta SK Slovakia
DE Germany HU Hungary NL Netherlands UK United Kingdom
DK Denmark IE Ireland NO Norway
doi:10.1371/journal.pone.0154197.t001
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Finally, we carried out a survey of some leading researchers in several European countries
with different levels of income per caput in order to try and determine the average cost of a
published paper in the five NCDs. We asked the researchers for their total annual research bud-
gets during the last five years (2009–13) and compared their responses with their outputs of
papers, fractionated according to the numbers of addresses. These results were then compared
with results of earlier surveys carried out with the same methodology [34, 35] that had been
used to determine the cost of a biomedical research paper in other subject areas.
Disease burden
In order to put our research results in context, we sought data on the burden from these non-
communicable respiratory diseases in Europe. Data on the 31 European countries were down-
loaded for the year 2010 from the IMHE website and revealed that these diseases accounted, on
average, for 4.7% of all Disability-Adjusted Life Years (DALYs), including 2.9% for COPD and
1.1% for asthma.
The countries suffering most from asthma are the UK (1.8% of DALYs), Ireland (1.7%),
Portugal, Cyprus and Sweden (1.6%). But the "accession" countries in eastern Europe suffer
much less, with the lowest burdens being in Lithuania, Bulgaria and Latvia (about 0.4%). In
COPD the relative burden is greatest in Denmark (4.7%), Switzerland (4.5%) and the UK
(4.2%), and least in the Baltic countries: Estonia (1.2%), Latvia (1.4%), and Lithuania and Fin-
land (2.0%). Burden of disease data are not given by the IHME for cystic fibrosis, but surveys in
European countries have been made of the incidence of the disease and reported by Farell [36].
The results for the EU27 Member States are shown in Fig 1 except for the seven countries with
populations below 4 million. They can be compared with the results of surveys of the genetic
mutation (DF508) that is mainly responsible for the disease [37]. Both surveys put Ireland in
first place; the UK and Italy also have a high incidence of CF. However, it is much lower in east-
ern Europe (Poland, Bulgaria and Romania) and in the Baltic countries (data for Latvia and
Lithuania not shown in Fig 1, but below 14 per million), although Estonia is an exception
Results
Respiratory research outputs and relative commitments
In the 12 years, 2002–13, there were 18,822 European RESPI papers in the WoS, representing
56% of the world total of 33,629. The European total was only 0.8% of their biomedical output
of 2,442,063 papers in 2002–13. The European output increased by 75%, and the international
fraction (i.e., the difference between the integer total for the 31 countries and the fractional
Table 2. List of sectors and sub-sectors used for the classification of research funders. GOV = government; PNP = private-non-profit;
INDY = industry.
Sector Code Sub-sector Sector Code Sub-sector
GOV GA Government agency PNP CH Collecting charity
GD Government department FO Endowed foundation
LA Local authority HT Hospital trustees
MI Mixed (academic)
INDY BT Biotechnology company NP Other non-proﬁt
IN Industrial (non-pharma)
IP Pharmaceutical
SN Subsidiary of industry
SP Subsidiary of pharma
doi:10.1371/journal.pone.0154197.t002
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total, divided by the former) doubled from 6.2% to 12.4%. These percentages are similar to
those for the other NCDs. Fig 2 shows the outputs of the 18 leading countries on a fractional
count basis and a comparison with the countries' wealth. The regression-line that best fits the
data on a least-squares basis is a power-law one with number of papers = 0.0012  GDP 0.9753, a
straight line on a log-log plot. The association is high (r2 = 0.80), but some countries publish
about twice what the regression line would suggest, such as the Netherlands (1447 compared
with 720), Sweden (886 compared with 446), and the UK (3924 compared with 2018), and oth-
ers such as Austria (140 compared with 365) less than half. These departures from the expected
numbers of papers are statistically highly significant (p<< 0.01%), based on a Poisson distri-
bution with one degree of freedom.
The outputs of the leading European countries in RESPI compared with their presence in
biomedical research, and the percentage of their DALYs attributable to non-communicable
respiratory diseases in 2010, are shown in Table 3 on an integer count basis. Values more than
sqrt(2), less than sqrt (0.5) or less than 0.5 are shown in a different font. All of the differences
between observed values and those expected on the basis of the European average are very
highly significant on the Poisson distribution with one d/f except for ES, GR, and PT where
p< 0.1%; for PL and IE where p< 5%, and FR, IT, FI and NO which are not statistically
significant.
Ten of these 18 countries have a relative commitment to respiratory research greater than
1.41: this means that there are many non-European countries with a much lower RC to the
subject area. But only two have their output in respiratory disease research above 1% of bio-
medical research (Sweden and the Netherlands) and their disease burden is 5% or higher, as is
Fig 1. Incidence of cystic fibrosis in selected European countries [36].
doi:10.1371/journal.pone.0154197.g001
Fig 2. Plot of RESPI paper output, 2002–13, against GDP for 18 European countries with fractional
counts above 100 papers.Note: BG, CY, CZ, EE, HR, IS, LT, LU, LV, MT, RO, SI and SK omitted. For
codes, see Table 1.
doi:10.1371/journal.pone.0154197.g002
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PLOS ONE | DOI:10.1371/journal.pone.0154197 April 25, 2016 6 / 15
that in eight other countries. On average, the percentage of biomedical research in RESPI is
only 15% of the percentage of the disease burden in DALYs.
The European countries varied in their concentration on the different respiratory diseases.
Data are given in Table 4 only for the three main ones: asthma (AST) with 7563 papers (40% of
the total of 18,822 RESPI papers), COPD (COP) with 4763 papers (25%) and cystic fibrosis (CYF)
with 3281 (17%). The countries that concentrate most on asthma are Finland and Poland, with
Ireland doing relatively little. In COPD, the leaders are Spain, Greece, the Netherlands and Nor-
way in terms of relative commitment, and in cystic fibrosis Ireland stands out, which is appropri-
ate, given its very high incidence of the disease (see Fig 2), together with Portugal and France.
Finland does very little CF research, which also accords with its low incidence of the disease.
Citation scores
European RESPI papers were slightly more highly cited than the world average. The number of
citations received in the five years following publication (Actual Citation Impact, ACI)
increased from 14.9 (+ 0.48) in 2002–03 to 16.2 (+ 0.56) in 2008–09 (figures in parentheses are
the standard errors of the mean, s.e.m.). These compare with world average values of 13.8 and
14.3. Within Europe, the best-cited papers were those from the UK, see Table 5, which gives
the mean ACI values and the percentages of the countries' papers with enough five-year cita-
tions (52) to put them in the top 5% of European papers, both on a fractional count basis. On
this basis, it is not possible to give values for the s.e.m. as the citation counts are each multiplied
by the fractional presence of each country in the paper.
A country's presence in the top 5% of papers is a rather more sensitive measure of impact
than mean citation score (ACI) as these are the important papers that are likely to influence
research and treatment.
Table 3. Percentage of their DALYs attributable to RESPI diseases in 2010 of 18 leading European countries and their percentage presence (inte-
ger counts) in non-communicable respiratory disease research and in all biomedical research, 2002–13.
% DALYs RESPI papers % of world Biomed papers % of world RC to RESPI RESPI/biomed, %
UK 7.1 5537 16.5 568306 9.3 1.77 0.97
DE 4.5 2474 7.4 491252 8.0 0.91 0.50
FR 4.2 2387 7.1 311583 5.1 1.39 0.77
IT 4.2 2372 7.1 294964 4.8 1.46 0.80
NL 5.3 2065 6.1 203963 3.3 1.84 1.01
ES 4.8 1742 5.2 200964 3.3 1.57 0.87
SE 5.0 1407 4.2 134251 2.2 1.90 1.05
BE 5.6 990 2.9 103663 1.7 1.73 0.96
DK 6.4 792 2.4 79304 1.3 1.81 1.00
CH 6.6 695 2.1 133055 2.2 0.95 0.52
PL 4.0 580 1.7 80694 1.3 1.31 0.72
GR 5.6 510 1.5 54017 0.9 1.72 0.94
FI 3.5 489 1.5 59216 1.0 1.50 0.83
NO 5.0 458 1.4 52619 0.9 1.58 0.87
AT 4.8 263 0.8 70010 1.1 0.68 0.38
IE 5.8 239 0.7 35507 0.6 1.22 0.67
PT 5.1 225 0.7 36704 0.6 1.11 0.61
HU 4.2 158 0.5 31979 0.5 0.90 0.49
The ratio = their relative commitment (RC) to RESPI. RC values and % of biomed > 1.41 in bold, < 0.71 in italics, < 0.5 in small italics. Codes are given in
Table 1.
doi:10.1371/journal.pone.0154197.t003
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Papers on COPDwere more highly cited than those in asthma and cystic fibrosis, see Table 6.
Citations on clinical guidelines
Of the 7184 references, 3744 were to the 23 clinical guidelines on COPD and 3052 were to the
20 on asthma. Table 7 shows the numbers of references (on a fractional count basis) from the
16 leading countries in each disease area, and for comparison, the numbers expected from the
countries' fractional count presence in COPD and asthma research, see Table 4.
The countries whose research contributes most to the evidence base of European clinical
guidelines, relative to its volume, are the UK and Denmark for both asthma and COPD. In
Table 4. Numbers of RESPI papers in the three main non-communicable respiratory diseases from each of the 18 leading European countries,
2002–13, fractional counts, and their relative commitment (RC) to research on each disease relative to their output in RESPI and to the European
average.
Number of papers Relative commitment
ISO2 AST COP CYF RESPI AST COP CYF
UK 1747 1068 921 3924 1.11 1.08 1.35
FR 848 320 555 1870 1.13 0.68 1.70
IT 736 560 361 1847 (0.99) 1.20 1.12
DE 686 364 415 1701 (1.00) 0.85 1.40
NL 643 591 163 1447 1.11 1.61 0.65
ES 504 585 143 1351 0.93 1.71 0.61
SE 503 217 77.8 886 1.41 (0.97) 0.50
BE 218 158 163 617 0.88 (1.01) 1.52
DK 227 154 90.5 487 1.16 1.25 (1.07)
PL 295 78.3 56.3 454 1.62 0.68 0.71
GR 167 166 35.6 383 (1.09) 1.71 0.53
CH 140 96.2 80.4 353 (0.99) (1.08) 1.31
FI 262 58 4.25 342 1.91 0.67 0.07
NO 138 109 14.6 267 1.29 1.61 0.31
PT 77.9 28 50.9 164 1.18 0.67 1.78
IE 29.7 24.5 90.1 155 0.48 0.62 3.33
AT 63.6 38.5 21.2 140 (1.13) (1.09) (0.87)
HU 65 16 10.4 109 1.48 0.58 0.55
Total 7563 4763 3281 18822
RC values > 2.0 in large bold, > 1.41 in bold, < 0.71 in italics, < 0.5 in small italics. Values with statistical signiﬁcance p < 0.001% shown underscored;
those not statistically different from unity shown in (parentheses), based on the Poisson distribution with one d/f. Country codes are given in Table 1.
doi:10.1371/journal.pone.0154197.t004
Table 5. Citation performance of 18 EUR31 countries in RESPI in 2002–09 with at least 50 citable papers, ranked by the percent with 52 or more
cites in the five years following publication (ACI) (Top 5%) rather than the mean value, fractional counts.
ISO ACI Top 5% % ISO ACI Top 5% % ISO ACI Top 5% %
UK 19.6 176.4 7.38 NO 14.7 5.4 3.80 FI 14.1 5.6 2.44
BE 18.2 24.8 6.74 ES 12.2 23.7 3.12 GR 10.1 3.6 1.75
DK 18.3 15.3 6.04 IT 12.9 35.1 3.18 HU 11.3 1.0 1.75
NL 17.9 45.1 5.32 IE 11.9 2.0 3.0 PL 8.5 3.9 1.69
CH 16.0 9.6 4.64 FR 9.8 34.9 2.80 AT 11.4 1.2 1.37
DE 13.9 43.9 4.04 SE 13.7 13.8 2.55 PT 8.3 0.3 0.33
doi:10.1371/journal.pone.0154197.t005
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asthma Finland's research is well-cited and in COPD this is so for Switzerland and Ireland. On
the other hand, research from Italy, Spain, Germany, Austria, France, Poland and Greece has
relatively less influence.
Funding of respiratory disease research
The analysis of funding, both explicit acknowledgments and ones implicit from the addresses,
shows that RESPI research does not attract much specific support, and over 37% of 2009–13
papers do not have it. The mean number of funders per paper overall was 1.98, and one paper
had over 100, but there was considerable variation between countries, see Fig 3.
The countries whose papers obtained the most funding, often given to their partners in
international collaborations, were three Scandinavian ones (Finland, Sweden and Norway),
and Denmark was in fifth place in this presentation. [Iceland would have been easily first, but
published only 16 papers in 2009–13 on a fractional count basis.] Central and Eastern Euro-
pean countries attracted little funding except from their own governments, though Hungary
was an exception, probably because of extensive international collaboration. Croatia (HR), in
southeast Europe, was relatively scientifically isolated, and 30 of its 49 papers acknowledged no
specific funding source.
Table 6. Five-year citation scores, and numbers of papers in the top 5% (52 cites), top 1% (121 cites) and top 0.2% (250 cites) in three respiratory
disease areas, 2002–09.
Disease Cit. ACI 52 c Top 5% 121 c Top 1% 250 c Top 0.2%
Asthma 5444 16.7 ±0.41 304 5.58 65 1.19 13 0.24
CF 2168 11.7 ±0.33 51 2.35 5 0.23 0 0.00
COPD 2728 19.5 ±0.79 202 7.40 43 1.58 9 0.33
RESPI 11207 16.0 ±0.29 573 5.11 113 1.01 21 0.19
doi:10.1371/journal.pone.0154197.t006
Table 7. Citations of European RESPI papers on 45 European respiratory clinical guidelines (CGs), and comparison with research outputs (Res):
percentages of EUR31 total.
Asthma COPD
Country Res,% CGs CGs,% Ratio Res,% CGs CGs,% Ratio
UK 23.1 608 40.5 1.75 22.4 683 36.1 1.61
NL 8.5 145 9.6 1.13 12.4 259 13.7 1.10
IT 9.7 119 7.9 0.81 11.8 152 8.0 0.68
ES 6.7 59.5 4.0 0.59 12.3 186 9.8 0.80
SE 6.7 105 7.0 1.05 4.6 85.4 4.5 0.99
DE 9.1 85.3 5.7 0.63 7.6 81.6 4.3 0.56
DK 3.0 86.1 5.7 1.91 3.2 86.4 4.6 1.41
FR 11.2 70.1 4.7 0.42 6.7 82.6 4.4 0.65
BE 2.9 45.3 3.0 1.05 3.3 86.1 4.5 1.37
FI 3.5 78.3 5.2 1.50 1.2 26.1 1.4 1.13
CH 1.9 17.4 1.2 0.62 2.0 61.4 3.2 1.61
NO 1.8 24.1 1.6 0.88 2.3 36.8 1.9 0.85
PL 3.9 13.5 0.9 0.23 1.6 19.3 1.0 0.62
GR 2.2 6.2 0.4 0.19 3.5 15.4 0.8 0.23
IE 0.4 5.5 0.4 0.92 0.5 14.3 0.8 1.47
AT 0.8 10.4 0.7 0.83 0.8 5.4 0.3 0.35
Ratios > 1.41 in bold, ratios < 0.71 in italics, < 0.5 in small italics.
doi:10.1371/journal.pone.0154197.t007
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An analysis was also conducted of the leading funders in terms of fractional credit, both
overall and for the leading countries, and of their sectors (government, private-non-profit,
industrial and international). The results for the leading funders are in Table 8, and the chart
showing how the leading countries' support is provided is in Fig 4. Estimates of annual expen-
diture are based on our estimates of the mean cost of a paper (see below). However, the expen-
diture by pharma companies is likely to be far higher as they will be carrying out intramural
work that does not lead to open publications.
In this analysis, it has been assumed that national public and private-non-profit funders
only support researchers in their own country, that European Union funding goes to the Euro-
pean countries whose addresses are on the paper in proportion to their number, and that
industrial funding can go to any country. It is striking that pharmaceutical companies appear
so prominently in this list, with six in the top 18.
Fig 3. Mean numbers of funding acknowledgments per paper, explicit and implicit, on the basis of
integer paper counts (INT) and of fractional counts (FRAC) for the 20 leading European producers of
RESPI papers, 2009–13.
doi:10.1371/journal.pone.0154197.g003
Table 8. List of leading funders of European respiratory disease research, 2009–13, with fractional counts of numbers of papers (N) and estimates
of annual research funding for European papers (€million).
Code Funders N € M/yr
GSW-IP-UK GlaxoSmithKline plc 233 12.1
CEC-GD-EU European Union 223 11.6
DOH-GD-UK UK Department of Health (including NHS hospitals) 169 8.8
ZAT-IP-UK AstraZeneca plc 157 8.1
DFG-GA-DE Deutsche Forschungsgesellschaft 126 6.5
NVP-IP-CH Novartis s.a. 123 6.4
ESS-GA-ES Spanish Institute Carlos III 97 5.0
INS-GA-FR French INSERM 85 4.4
DUA-CH-NL Netherlands Asthma Foundation (charity) 84 4.4
MRC-GA-UK UK Medical Research Council 84 4.4
BOI-IP-DE Boehringer Ingelheim AG 79 4.1
WEL-FO-UK Wellcome Trust, London 78 4.0
PFZ-IP-US Pﬁzer Inc. 68 3.5
MRK-IP-US Merck Inc. 64 3.3
Y59-NP-ES Spanish non-proﬁt organisations 51 2.7
FSK-LA-BE Fonds voor Wetenschappelijk Onderzoek Vlaanderen 50 2.6
SHL-CH-SE Swedish Heart and Lung Foundation (charity) 47 2.4
FRC-CH-FR Vaincre la Mucoviscidose (French Cystic Fibrosis F'd'n) 46 2.4
Z08-MI-PL Polish universities 45 2.4
TAK-IP-JP Takeda Ltd 42 2.2
AST-CH-UK Asthma UK (charity) 41 2.1
FCU-CH-IT Fondazione Italiana per la Fibrosi Cistica (charity) 41 2.1
POM-GD-PL Polish Ministry of Science and Higher Education 40 2.1
SHD-GD-UK Scottish government 40 2.1
doi:10.1371/journal.pone.0154197.t008
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Support from the European Union (EU) comes from a variety of sources, mostly but not
exclusively the Framework Programmes. Table 9 shows the countries that receive the most sup-
port (fractional count of papers), and also the ones where the EU support is proportionately
the greatest (Latvia, Slovakia and the Czech Republic).
This table reveals clearly that the large countries in scientific output received by far the bulk
of EU support (the top seven obtained almost two thirds of the total), but some of the smaller
countries, notably Latvia, Slovakia and the Czech Republic, depended highly on the EU for
their research on RESPI.
Our survey of leading researchers elicited some 30 responses, of which 22 gave useable data
(some suggested unrealistically high or low costs for a paper). As expected, the responses from
high-income countries (Norway and Switzerland) gave a figure (€412 k) higher than that from
the researchers in middle-income countries (Belgium and Finland; €260 k), and much higher
than that from respondents in low-income countries (Bulgaria, Czech Republic, Romania, Slo-
vakia and Slovenia; €142 k). These mean costs parallel the differences in income per caput
between the groups, but are less divergent. Since the large majority (about 85%) of all RESPI
papers came from middle-income countries (mainly France, Germany, Italy and the UK), the
overall average cost per paper worked out at close to their figure, at €255k. (This was also simi-
lar to results found in earlier surveys, adjusted for inflation [34,35].) This means that the aver-
age annual research expenditure on respiratory diseases in Europe during these years was of
the order of €407 million, barely one fifteenth of that on cancer research (€5977 million p.a.).
Since the burden from respiratory diseases in Europe is just over one quarter of that from can-
cer, it is apparent that respiratory disease research is relatively under-funded. If it were to
Fig 4. Main sectors supporting respiratory disease research in 11 leading European countries, 2009–
13.GOV = public sector (including local authorities), PNP = private-non-profit, CEC = European Union,
INDY = industry (mainly pharma).
doi:10.1371/journal.pone.0154197.g004
Table 9. European Union support for respiratory disease research, 2009–13: numbers of papers (left columns) and percent of papers for individual
countries (EU, %, right columns).
Country Papers EU,% Country Papers EU,% Country Papers EU,%
UK 31.5 1.7 CH 7.1 4.1 IE 2.8 3.0
DE 27.2 3.5 PL 5.8 2.3 LV 2.0 47.1
IT 22.8 2.6 FI 5.1 3.8 IS 0.7 4.3
NL 17.3 2.4 SK 4.7 20.3 RO 0.5 1.1
FR 17.0 2.1 DK 4.6 1.7 SI 0.4 1.0
ES 16.9 2.3 CZ 4.5 11.4 LT 0.4 2.0
BE 12.4 3.9 NO 4.0 2.9 EE 0.3 5.2
SE 10.8 2.6 HU 3.9 6.9 CY 0.2 2.9
GR 9.2 4.5 AT 3.4 6.1 BG 0.1 0.4
PT 9.0 8.4 Total 224.5 2.7
None of the RESPI papers from Croatia, Luxembourg and Malta were funded by the EU.
doi:10.1371/journal.pone.0154197.t009
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receive as much research money as cancer in relation to its disease burden, it would need an
additional €1225 million per year, or three times its existing research budget.
Discussion
This study has mapped the main features of research into non-communicable respiratory dis-
eases in Europe in 2002–13, the outputs of the 31 countries and their citation scores, and the
funding sources for papers in the last five years (2009–13). The study has some limitations. We
were not able to check how comprehensive the filter was at capturing relevant papers, and
indeed we expect that it will have omitted some basic research papers where the title or the
journal did not directly indicate the name of the disease. However, this limitation affects other
disease-related research topics. The restriction of the database to articles and reviews is stan-
dard bibliometric practice, although it is arguable that other document types such as editorials,
letters and meeting abstracts sometimes contain interesting results, and are indeed occasionally
cited among the references on clinical guidelines.
The large number of funding bodies acknowledged on the Scandinavian papers is attribut-
able to the many small (and some large) endowed foundations in these countries. In Finland,
private-non-profit sources accounted for over half the total funding (54%), and most of these
were endowed foundations. (So far, we have encountered over 50 different named Finnish
foundations, although not all of them support respiratory disease research.) In the former
socialist countries of central and eastern Europe, although there are some private-non-profit
funders, notably professional associations, there does not appear to be a tradition of public
charitable funding of medical research, or the creation of foundations by wealthy families and
individuals. The fiscal regime may also not be so favourable to such activities as it is in western
Europe (and north America).
Of the main respiratory diseases, asthma is better established as a research subject than
COPD; its integer count output from the EUR31 countries was 8489 papers in 2002–13, or
0.35% of all biomedical research output. This is still much lower than its disease burden of
1.07%, but the ratio is more favourable than for COPD which had 5286 papers or 0.22% com-
pared with a burden of 2.95%, an adverse ratio of 13.6 compared with 3.1 for asthma.
Why should this be? "COPD mainly affects people over the age of 40 and becomes more
common with increasing age. The average age when it is formally diagnosed is around 67
years. It is more common in men than women. COPD accounts for more time off work than
any other illness and a flare-up (exacerbation) of COPD is one of the most common reasons
people seek emergency hospital assistance" [38]. On the other hand, asthma affects people of
all ages, and in England one in five sufferers are children, over 1.1 million, or one in 11 chil-
dren. It is not surprising, therefore, that asthma has a far higher public profile, and there are
medical research charities to support asthma research whereas COPD has largely to rely on
public funding, plus support from pharma companies. Moreover, because it is so often caused
by smoking, it does not attract public sympathy in the same way as asthma.
There are also charities in at least eight European countries (Belgium, France, Germany, Ire-
land, Italy, Netherlands, Sweden and the UK) that support research in cystic fibrosis, some-
times called mucoviscidosis. Inevitably this disease mainly affects young people as life
expectancy for patients is quite low, though it has increased to about 40 years [39] as better
treatments have become available.
It appears, therefore, that COPD has an image problem, and does not attract research fund-
ing from the European public, who are understandably more concerned with the health of chil-
dren than with that of old men, many of whom have been smokers. However, COPD is an
unpleasant disease, and as the quotation above suggests, it is an expensive one to treat because
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of the numbers of patients and the difficulty of doing more than provide palliative care. It
should therefore have a greater claim on public sources of research funding. There should not
be a problem in finding applications of high quality, as COPD research is actually better cited
than papers in asthma or CF, as Table 6 shows.
We have not analysed the outputs by the type of research, such as epidemiology, genetics,
pharmaceutical and other treatments, and palliative care. This would provide information on
which aspects of research may be neglected relative to others and might suggest changes in
approach in individual countries. In particular, this would show the types of research that are
most frequently cited on clinical guidelines, and so are of medical utility.
Conclusions
The main conclusion is that respiratory disease research is seriously under-funded. The
research outputs of the leading European countries vary between 0.4% of all their biomedical
research (Austria) and just over 1.0% (Netherlands, Sweden and Denmark), but these values
are all very small compared with the European disease burden of 4.7% of all DALYs. If respira-
tory disease research were to be funded on the same scale as cancer, relative to its disease bur-
den, funding would need to be quadrupled. And within RESPI research, the main need is for
more work on COPD, which is even more under-resourced than asthma research but causes
more distress and expense.
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